Meeting space has been assigned to provide a Symposia supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc. during the Oncology Nursing Society’s (ONS) 49th Annual Congress, April 24 – April 28, 2024 in Washington, D.C. The Oncology Nursing Society's assignment of meeting space does not imply product endorsement.

There are no fees for participating in or receiving credit for this CE activity, however, you must be registered for 49th Annual ONS Congress to attend. To pre-register for this lunch symposium, click the button below or scroll to the bottom of this page to complete the registration form.

Activity Description:

Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.

Don’t miss this opportunity to compete with and against your peers for prizes as you expand your knowledge and elevate your ability to provide holistic, evidence-based care, facilitate the smooth integration of CAR T-cell therapies in diverse clinical settings, and ultimately optimize patient outcomes

Earn up to 1.5 NCPD contact hours.

Space is limited, so  REGISTER TODAY!

Agenda

  • Keeping Current the Advances in NHL and MM
    Supporting patients through the diversity of the disease (indolent vs aggressive disease)
  • Keeping Current with Clinical Guidelines: Navigating CART in MM
    >
    Supporting patients through clinical trial enrollment hesitations
  • Optimizing Patient Outcomes: Managing NHL and MM TEAEs
    >
    Addressing barriers to care through effective patient education
  • The Future of CAR T-cell Therapy
    > Strategies and perspectives for CAR T-cell therapy in community and outpatient settings
  • Key Takeaways and Conclusions
  • Q&A with Expert Faculty

This activity is intended for academic and community nurses and NPs who treat and manage patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.

After completing this CE activity, the participant should be better able to:

    • Describe the process of CAR T-cell therapy, including its manufacturing, administration, and mechanism of action in NHL and MM
    • Align CAR T-cell therapy choices and new and emerging treatments, including bispecific antibodies and combination therapies (e.g., TCEs and CELMoD) with NCCN clinical guidelines, by incorporating the latest clinical evidence, drug mechanism of action, patient preferences, and disease subtypes for both NHL and MM
    • Employ effective patient education in differentiating available treatment options, addressing clinical trial participation, and providing resources for patient/caregiver support
    • Integrate strategies to identify and manage common treatment-emergent events and long-term toxicities related to CAR T-cell therapy
    • Incorporate action-based plans to address challenges associated with transitioning CAR T-cell therapy to community practices and outpatient settings, thereby improving patient access

Joint Accreditation with Commendation LogoIn support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 1.5 contact hours in the area of pharmacology.

ILNA Coding

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
*1.5 points: Oncologic Emergencies (OCN, CPHON, AOCNP); Oncology Nursing Practice (OCN); Professional Practice/Performance (BMTCN, AOCNP); Roles of the APRN (AOCNP); Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP); Treatment (OCN, CBCN, AOCNP, CPHON)
*1.5 points: Foundations of Transplant (BMTCN)

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing. Please also note that nurses’ individual learning plans are linked to their credential’s test blueprint (content outline). Current ONCC test content outlines can be found on the ONCC website:

OCN® | https://www.oncc.org/files/2022OCNOutline.pdf

CPHON® | https://www.oncc.org/files/CPHONTestContentOutline.pdf

CBCN® | https://www.oncc.org/files/2022CBCNOutline.pdf

BMTCN® | https://www.oncc.org/files/2022BMTCNOutline.pdf

AOCNP® | https://www.oncc.org/files/2020AOCNPTestContentOutline.pdf

This activity is provided by MLI

All disclosures will be provided to learners prior to the live presentation on Thursday, April 25, 2024.

Support Statement
This activity is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Location & Time

49th Annual ONS Congress
Thursday, April 25, 2024
12:15 PM – 1:45 PM

Marquis Ballroom Salon 1-4
Marriott Marquis | Washington, DC

Faculty

Rayne H. Rouce, MD, BS
Associate Professor of Pediatrics
Texas Children’s Cancer Center
Center for Cell and Gene Therapy
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX
 

Sanjay Sharma, MDSanjay Sharma, MD
Hematologist-Oncologist
Providence St. Jude
Fullerton, CA

 

 

Laura J. Zitella, MS, RN, ACNP-BC
Nurse Practitioner
Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program
Associate Clinical Professor
University of California, San Francisco
San Francisco, CA

Event Registration

Scroll to Top